CD8+ memory T cell therapy (Stanford University)

N/A

Report date: 2024/06/22 20:00:06

Base Information

Drug NameCD8+ memory T cell therapy (Stanford University)
Drug Alias NameCD8+ Memory T CellsEnriched for CD8+CD45RA memory T cellsAllogeneic phenotypic CD8+ memory T cellsAllogeneic phenotypic CD8+ memory T cell therapyEnriched for CD8+CD45RA memory T cell therapy
ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Memory T cell therapy
Mechanisms of ActionCell replacementsCluster of differentiation 8 modulators
TargetsCluster of differentiation 8
Therapy Area/IndicationsMyelodysplastic SyndromesLeukemia, Myeloid, AcuteLeukemia, Myelogenous, Chronic +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesStanford University
China Registration ClassN/A

Develop Information

Active CompaniesNational Institutes Of HealthNational Cancer Institute
Inactive CompaniesN/A
Active IndicationsMyelodysplastic SyndromesLeukemia, Myeloid, AcuteLeukemia, Myelogenous, Chronic +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A